Literature DB >> 9632585

Identification of new cytotoxic T-cell epitopes on the 38-kilodalton lipoglycoprotein of Mycobacterium tuberculosis by using lipopeptides.

D P da Fonseca1, D Joosten, R van der Zee, D L Jue, M Singh, H M Vordermeier, H Snippe, A F Verheul.   

Abstract

Induction of cytotoxic T lymphocytes (CTLs) by vaccination has been shown to protect against bacterial, viral, and tumoral challenge. The aim of this study was to identify CTL epitopes on the 38-kDa lipoglycoprotein from Mycobacterium tuberculosis. The identification of these CTL epitopes was based on synthesizing peptides designed from the 38-kDa lipoglycoprotein, with known major histocompatibility complex class I (MHC-I) binding motifs (H-2Db), and studying their ability to up-regulate and stabilize MHC-I molecules on the mouse lymphoma cell line RMA-S. To improve the capacity of the identified peptides to induce CTL responses in mice, palmitic acid with a cysteine-serine-serine spacer amino acid sequence was attached to the amino terminus of the peptide. Two of five peptides with H-2Db binding motifs and their corresponding lipopeptides up-regulated and stabilized the H-2Db molecules on RMA-S cells. Both lipopeptides, in combination with incomplete Freund's adjuvant, induced CTL responses in C57BL/6 (H-2(b)) mice. Moreover, the lipopeptide induced stronger CTL responses than the peptide. The capacity of the various lipopeptides to induce CTL displayed a good relationship with the ability of the (lipo)peptide to up-regulate and to stabilize H-2Db molecules. The capacity of the peptides and lipopeptides to up-regulate and stabilize MHC-I expression can therefore be used to predict their potential to function as a CTL epitope. The newly identified CTL epitopes and their lipid derivatives provide us with important information for future M. tuberculosis vaccine design.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9632585      PMCID: PMC108332     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

Review 1.  Solid phase peptide synthesis of lipopeptide vaccines eliciting epitope-specific B-, T-helper and T-killer cell response.

Authors:  K H Wiesmüller; W G Bessler; G Jung
Journal:  Int J Pept Protein Res       Date:  1992 Sep-Oct

2.  In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides.

Authors:  X Zhou; L Berg; U M Motal; M Jondal
Journal:  J Immunol Methods       Date:  1992-08-30       Impact factor: 2.303

3.  Phagocytic processing of bacterial antigens for class I MHC presentation to T cells.

Authors:  J D Pfeifer; M J Wick; R L Roberts; K Findlay; S J Normark; C V Harding
Journal:  Nature       Date:  1993-01-28       Impact factor: 49.962

4.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules.

Authors:  J Ruppert; J Sidney; E Celis; R T Kubo; H M Grey; A Sette
Journal:  Cell       Date:  1993-09-10       Impact factor: 41.582

5.  Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein.

Authors:  F Martinon; H Gras-Masse; C Boutillon; F Chirat; B Deprez; J G Guillet; E Gomard; A Tartar; J P Levy
Journal:  J Immunol       Date:  1992-11-15       Impact factor: 5.422

6.  Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells.

Authors:  M C Feltkamp; H L Smits; M P Vierboom; R P Minnaar; B M de Jongh; J W Drijfhout; J ter Schegget; C J Melief; W M Kast
Journal:  Eur J Immunol       Date:  1993-09       Impact factor: 5.532

7.  Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection.

Authors:  J L Flynn; M M Goldstein; K J Triebold; B Koller; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

Review 8.  Tuberculosis: commentary on a reemergent killer.

Authors:  B R Bloom; C J Murray
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

9.  In vivo priming of cytotoxic T lymphocyte responses in relation to in vitro up-regulation of major histocompatibility complex class I molecules by short synthetic peptides.

Authors:  X Zhou; U M Abdel Motal; L Berg; M Jondal
Journal:  Eur J Immunol       Date:  1992-12       Impact factor: 5.532

10.  Major histocompatibility complex conformational epitopes are peptide specific.

Authors:  B Catipović; J Dal Porto; M Mage; T E Johansen; J P Schneck
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

View more
  4 in total

1.  Induction of cell-mediated immunity against Mycobacterium tuberculosis using DNA vaccines encoding cytotoxic and helper T-cell epitopes of the 38-kilodalton protein.

Authors:  D P Fonseca; B Benaissa-Trouw; M van Engelen; C A Kraaijeveld; H Snippe; A F Verheul
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Administration of superantigens protects mice from lethal Listeria monocytogenes infection by enhancing cytotoxic T cells.

Authors:  S Okamoto; S Kawabata; I Nakagawa; S Hamada
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

Review 3.  Peptide-Based Vaccines for Tuberculosis.

Authors:  Wenping Gong; Chao Pan; Peng Cheng; Jie Wang; Guangyu Zhao; Xueqiong Wu
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

4.  Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine.

Authors:  Weihsu Chen; Leaf Huang
Journal:  Mol Pharm       Date:  2008-02-12       Impact factor: 4.939

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.